GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed price. Currency in GBp
1,651.60
+24.40 (+1.50%)
As of 3:03PM BST. Market open.
Stock chart is not supported by your current browser
Previous close1,627.20
Open1,631.40
Bid1,651.20 x 0
Ask1,651.60 x 0
Day's range1,628.80 - 1,652.40
52-week range1,408.80 - 1,767.00
Volume2,064,149
Avg. volume8,449,379
Market cap82.391B
Beta (3Y monthly)0.85
PE ratio (TTM)18.60
EPS (TTM)88.80
Earnings date30 Oct 2019
Forward dividend & yield0.76 (4.63%)
Ex-dividend date2019-08-08
1y target est1,644.50
  • Here's Why GlaxoSmithKline (LON:GSK) Can Manage Its Debt Responsibly
    Simply Wall St.

    Here's Why GlaxoSmithKline (LON:GSK) Can Manage Its Debt Responsibly

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • Never mind the Cash ISA. I think these stock market stalwarts will help you beat a recession
    Fool.co.uk

    Never mind the Cash ISA. I think these stock market stalwarts will help you beat a recession

    Paul Summers picks out three defensive stocks that should hold their own in the event of a Brexit-linked recession.

  • Reuters - UK Focus

    UPDATE 1-Kenya becomes third African nation to introduce malaria vaccine

    Kenya on Friday began adding a malaria vaccine to its routine immunization schedule for babies and toddlers, becoming the third African country to roll out the vaccine for a disease that threatens children across the continent. Malaria, which kills one child globally every two minutes, is the top killer of children under five in the east African country. The vaccine - the world's first against malaria - will be administered to children under two and could be crucial to efforts to combat the disease, health officials said.

  • Business Wire

    Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma

    GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma. Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the US. Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “Children with severe eosinophilic asthma currently have limited treatment choices available to them.

  • Reuters

    Factbox: Purdue OxyContin settlement would rank among largest in pharma history

    The settlement could be valued at up to $12 billion, they said, which would make it the largest such settlement in U.S. pharmaceutical history. The following are some of the largest previous U.S. legal settlements involving the pharmaceutical industry. * Merck & Co $4.85 billion, 2007 - Three years after it pulled its widely used arthritis pain drug Vioxx from the market over safety concerns and following several product liability trials, Merck agreed to pay nearly $5 billion to settle most of the 60,000 lawsuits alleging that Vioxx caused heart attacks and strokes.

  • Reuters - UK Focus

    Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane

    Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designation https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0 last year.

  • Is Glaxosmithkline a high quality investment?
    Stockopedia

    Is Glaxosmithkline a high quality investment?

    A company with a high Quality Rank has strong cash-generation, consistent profits, high rates of return on investment, high margins and robust financial health8230;

  • Reuters - UK Focus

    UPDATE 2-JD Sports leads FTSE 100 higher, rate cut hopes support

    London's FTSE 100 overcame early losses to close higher on Tuesday as hopes of imminent interest rate cuts from major central banks buoyed sentiment, while JD Sports jumped to an all-time high on upbeat results. The blue-chip index added 0.4%, with JD Sports gaining 8.8% after its gym clothing and premium-branded fashion helped it post higher profit and offset UK retail sector gloom. The FTSE 250 rose 0.3%, helped in part by a nearly 13% surge in Cairn Energy as strong half-year results led to a production target upgrade.

  • Reuters - UK Focus

    UPDATE 2-UK bluechips give up gains as sterling strengthens

    London's FTSE 100 fell on Monday as the pound ploughed ahead after unexpectedly robust economic data and as no-deal Brexit worries tempered, leaving internationally-focussed stocks in the dumps. The blue-chip index lost 0.6%, shedding earlier gains and lagging its European peers, due to steep falls in pharmaceutical shares AstraZeneca, GlaxoSmithKline , and consumer goods giant Unilever. The FTSE 250 index dipped 0.1%, though losses were limited thanks to a 10.4% surge in Intu Properties after the Times reported that private equity firm Orion Capital Managers was looking to buy the shopping centre operator.

  • I see investing in FTSE 100 shares like GSK as a marathon, not a sprint
    Fool.co.uk

    I see investing in FTSE 100 shares like GSK as a marathon, not a sprint

    Long-term investing in shares like GlaxoSmithKline plc (LON:GSK) requires preparation, patience and discipline to successfully cover the long distance ahead.

  • Tempted by the Glaxo share price? Here’s what you need to know
    Fool.co.uk

    Tempted by the Glaxo share price? Here’s what you need to know

    Shares in GlaxoSmithKline plc (LON:GSK) look tempting after their recent rally, but you should read this before you buy the stock.

  • Why I think this FTSE 250 stock could trash the GSK share price
    Fool.co.uk

    Why I think this FTSE 250 stock could trash the GSK share price

    I love GlaxoSmithKline plc (LON: GSK). But I reckon this FTSE 250 (INDEXFTSE: MCX) stock could beat it in the growth stakes.

  • Reuters - UK Focus

    REFILE-UPDATE 2-Strong sterling knocks FTSE 100 despite trade lull

    London's FTSE 100 slipped on Thursday as a surge in sterling pushed exporter stocks lower, missing out on a global rally led by growing hopes of a resolution to the U.S.-China trade dispute. The FTSE 100 slid 0.6%, with multinationals including spirits company Diageo, pharma giants AstraZeneca and GlaxoSmithKline slipping about 3% as a strong pound meant the value of their U.S. earnings was lower. Stocks trading without dividend entitlement on the day such as BHP, Glencore and Micro Focus fell between 1.2%-3%, weighing heavily on the blue-chip index.

  • 3 International Stocks Worth Watching
    Motley Fool

    3 International Stocks Worth Watching

    It pays to diversify your portfolio.

  • Reuters - UK Focus

    GRAPHIC-UK Plc's discount steepens as political crisis over Brexit deepens

    Growing worries about Britain crashing out of the European Union and a general election that could usher in a new government and major changes to UK Plc have steepened the discount for London-listed companies with exposure to the domestic economy. Shares in London-listed companies that make the bulk of their revenue in Britain have suffered since the June 2016 referendum on European Union membership.

  • Forget Bitcoin or gold! I’d buy these FTSE 100 dividend stocks in my ISA instead
    Fool.co.uk

    Forget Bitcoin or gold! I’d buy these FTSE 100 dividend stocks in my ISA instead

    Desperate times mean desperate investors reach for so-called safe havens. GlaxoSmithKline plc (LON:GSK) and Legal & General plc (LON:LGEN) may not be sexy but they are solid.

  • Reuters - UK Focus

    UPDATE 1-AstraZeneca lupus drug shows promise after set-back last year

    AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus met the main goal in a late-stage study, an encouraging sign after it failed to meet its main target in the final stage of another trial last year. The British drugmaker said anifrolumab under the TULIP 2 program helped patients with systemic lupus erythematosus, commonly known as SLE. The drug had failed to meet its main goal in the final stage of one of the two clinical trials under the TULIP program last year https://in.reuters.com/article/us-astrazeneca-anifrolumab/astrazeneca-lupus-drug-fails-to-meet-main-goal-in-study-idINKCN1LG0MM.

  • Why I’d still buy the GSK share price after its 10% rise
    Fool.co.uk

    Why I’d still buy the GSK share price after its 10% rise

    G A Chester still sees good value in GlaxoSmithKline plc (LON:GSK) and in a smaller-cap sector peer.

  • Reuters - UK Focus

    UPDATE 2-AstraZeneca respiratory business gets boost from 3-drug inhaler results

    Prospects for AstraZeneca's respiratory treatments business improved on Wednesday as a three-drug inhaler was shown to ease smoker's lung and U.S. regulators granted its injectable asthma drug Fasenra special status for a rare lung condition. AstraZeneca said the late-stage ETHOS trial of triple-drug therapy Breztri Aerosphere, formerly known as PT010, helped patients suffering from chronic obstructive pulmonary disease (COPD), in a challenge to Glaxosmithkline’s Trelegy Ellipta.

  • Should you buy or sell the GSK share price?
    Fool.co.uk

    Should you buy or sell the GSK share price?

    Roland Head explains why big changes could make GlaxoSmithKline plc (LON: GSK) a compelling buy.

  • Do GlaxoSmithKline's (LON:GSK) Earnings Warrant Your Attention?
    Simply Wall St.

    Do GlaxoSmithKline's (LON:GSK) Earnings Warrant Your Attention?

    For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

  • Reuters - UK Focus

    UPDATE 2-GSK builds oncology pipeline as drug shown to help myeloma patients

    GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business. Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion last year and an agreement in February to pay up to 3.7 billion euros ($4.09 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

  • GSK builds oncology pipeline as drug shown to help myeloma patients
    Reuters

    GSK builds oncology pipeline as drug shown to help myeloma patients

    Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion (£4.2 billion) last year and an agreement in February to pay up to 3.7 billion euros (£3.3 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more